The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions

• DOI: 10.1039/c7dt04614f
• Publication Date: 2018-05-31T16:35:25Z
• Authors: Elisabetta Gabano; Mauro Ravera; Francesca Trivero; Stefano Tinello; Andrea Gallina; Ilaria Zanellato; Marzia B. Gariboldi; Elena Monti; Domenico Osella
• Keywords: 0303 health sciences; Dose-Response Relationship, Drug; Molecular Structure; Organoplatinum Compounds; 610; Antineoplastic Agents; Apoptosis; 540; Hypoxia-Inducible Factor 1, alpha Subunit; 3. Good health; Clofibric Acid; Inhibitory Concentration 50; Oxidative Stress; 03 medical and health sciences; Cell Line, Tumor; Humans; PPAR alpha; Prodrugs; Cisplatin; Hypoxia

The cisplatin/clofibrato combos are multi-action Pt(iv) complexes active on a panel of human tumor cell lines, also under hypoxic conditions.